Italian hedge fund BxWorld Fund has entered a position in Soligenix (Nasdaq: SNGX), a biotech company with some interesting products for the cure of cancer and a range of products against bioterrorism and radioactive warfare. Luca Fer, BxWorld's fund manager, says: "We consider the company a target also for the USA government or some defense institution". We think that the target price is $11.00.

Soligenix  is an interesting stock at present. Now trading with a market value of just $16.07M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Soligenix Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For SNGX, the company currently has $7.14 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has $8.41 million in total assets, balanced by $2.59 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Soligenix, Inc. saw -$1.63 million in free cash flow last quarter, representing a quarterly net change in cash of -$1.63 million. Perhaps most importantly where cash movements are concerned, the company saw about -$1.63 million in net operating cash flow.

Soligenix Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw $1.33 million in total revenues. That represents a quarterly year/year change in revenues of -0.49 in sequential terms, SGNX saw sales decline by -0.22.

But what about the bottom line? After all, that’s what really matters in the end. Soligenix, Inc.  is intriguing when broken down to its core data. The cost of selling goods last quarter was 1.09 million, yielding a gross basic income of 243,569. For shareholders, given the total diluted outstanding shares of 5.47 million, this means overall earnings per share of -0.32. Note, this compares with a consensus analyst forecast in earnings per share for its next fiscal quarterly report.

Is Soligenix Valuation Attractive?

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -2 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of $9.999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon..